Gonococcal antimicrobial susceptibility surveillance in Europe, 2013
During 2013, the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP) followed the biannual decentralised and centralised testing model used in previous years, requesting participating laboratories to collect gonococcal isolates during two periods (April/May and October/November).
Gonococcal antimicrobial susceptibility surveillance in Europe, 2014
The surveillance of Neisseria gonorrhoeae antimicrobial susceptibility in the European Union/European Economic Area (EU/EEA) has been co-ordinated by the European Centre for Disease Prevention and Control (ECDC) since 2009.
EU/EEA capacity for the surveillance of hepatitis B and C using molecular methods
In order to explore whether the current capacity for EU/EEA-wide molecular characterisation for surveillance of HBV and HCV is sufficient to be feasible and what gaps need to be addressed, a survey of EU/EEA Member States was conducted to assess their laboratory capacity and needs in relation to the molecular characterisation of hepatitis B and C.
Developing a reporting system for the surveillance of HIV drug resistance in Europe
A pilot project was carried out to investigate the feasibility of HIVDR surveillance in EU/EEA countries and to make recommendations for the design and implementation of a potential future HIVDR surveillance system at the European level.
Gonococcal antimicrobial susceptibility surveillance in Europe, 2017
The overall aim of Euro-GASP is to strengthen the surveillance of gonococcal antimicrobial susceptibility in EU/EEA Member States in order to provide quality-assured data to inform gonorrhoea treatment guidelines. This report presents the results from the 2017 gonococcal antimicrobial susceptibility sentinel surveillance.
Gonococcal antimicrobial susceptibility surveillance in Europe, 2015
The European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP) follows a decentralised and centralised testing model. In 2015, 24 EU/EEA Member States participated in Euro-GASP, 17 through decentralised testing.
Rapid risk assessment: Chlamydia trachomatis false-negative test results by Aptima Combo 2 CT/NG assay (Hologic) in the EU/EEA, 2019
In April 2019, Finland reported false-negative or equivocal results in patients tested for Chlamydia trachomatis (CT) using Aptima Combo 2 Assay (Hologic) (AC2).
Euro-GASP external quality assessment scheme for Neisseria gonorrhoeae antimicrobial susceptibility testing
External quality assessment (EQA) is an essential part of any laboratory-based surveillance system, allowing for the monitoring of performance and comparability of results from participating laboratories, identification of potential issues, and deployment of resources and training where necessary.
Gonococcal antimicrobial susceptibility surveillance in Europe 2011
This report presents the results from the 2011 gonococcal antimicrobial susceptibility surveillance programme (Euro-GASP) and a summary of the second distribution from the 2011 external quality assurance (EQA) scheme.